Clinical Trial: the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06378840) titled 'the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer' on April 10.

Brief Summary: To explore the predictive value of immune cells by single-cell sequencing on the outcome of locally advanced cervical cancer treated by concurrent chemoradiotherapy Followed by PD-1 inhibitor

Study Type: Observational

Condition: * Locally Advanced Cervical Carcinoma

* Concurrent Chemoradiotherapy

* Immunotherapy

Intervention: Radiation: Nab-paclitaxel/Platinum, Sintilimab

Sintilimab Combined With Concurrent Nab-paclitaxel/Platinum-based Chemoradiotherapy

Recruitment Status: Recruiting

Published by HT Digital Content Services...